Dr Jenny Shannon

Clinical Senior Lecturer
Medicine, Nepean Clinical School

Telephone +61 2 4734 3500

Map

Selected grants

2013

  • Improving patient outcomes for patients with Gastrointestinal (GI) cancer through clinical trials research: An application on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG); Goldstein D, Simes R, Abdi E, Ackland S, Pavlakis N, Shannon J; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2009

  • Phase III Study in patients with Locally Advanced Pancreatic cancer: Gemcitabine +/- chemoradiotherapy and +/- erlotinib; Goldstein D, Shannon J, Spry N, Padbury R, Shannon J, Biankin A, Kneebone A, FitzGerald P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2007

  • Phase II study of chemotherapy and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer; Shannon J, Goldstein D, Shannon J, Lipton L, Ackland S, Karapetis C, Van Hazel G; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Elander, N., Aughton, K., Ghaneh, P., Neoptolemos, J., Palmer, D., Cox, T., Campbell, F., Costello, E., Halloran, C., Mackey, J., Shannon, J., et al (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118(8), 1084-1088. [More Information]
  • McNamara, M., Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L., Okusaka, T., Knox, J., Wagner, D., Cunningham, D., Shannon, J., et al (2017). Systemic therapy in younger and elderly patients with advanced biliary cancer: Sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer, 17(1), 1-9. [More Information]
  • Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L., Klumpen, H., Lohse, A., Nashan, B., Primrose, J., Schrum, S., Shannon, J., et al (2015). Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 15(1), 1-8. [More Information]
  • Greenhalf, W., Ghaneh, P., Neoptolemos, J., Palmer, D., Cox, T., Lamb, R., Garner, E., Campbell, F., Mackey, J., Costello, E., Shannon, J., et al (2014). Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. Journal of the National Cancer Institute, 106(1), 1-10. [More Information]
  • Ringash, J., Au, H., Siu, L., Shapiro, J., Jonker, D., Zalcberg, J., Moore, M., Strickland, A., Kotb, R., Jeffery, M., Shannon, J., El-Tahche, F., et al (2014). Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer, 120(2), 181-189. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Oddone, N., Morgan, G., Palme, C., Perera, L., Shannon, J., Wong, E., Gebski, V., Veness, M. (2009). Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer, 115(9), 1883-1891. [More Information]
  • Dear, R., Wilcken, N., Shannon, J. (2008). Beyond chemotherapy: Demystifying the new 'targeted' cancer treatments. Australian Family Physician, 37(1-2), 45-49. [More Information]
  • Shannon, J. (2006). Traffic fine. The Lancet, 367(9520), 1456-7. [More Information]

2018

  • Elander, N., Aughton, K., Ghaneh, P., Neoptolemos, J., Palmer, D., Cox, T., Campbell, F., Costello, E., Halloran, C., Mackey, J., Shannon, J., et al (2018). Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 118(8), 1084-1088. [More Information]

2017

  • McNamara, M., Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L., Okusaka, T., Knox, J., Wagner, D., Cunningham, D., Shannon, J., et al (2017). Systemic therapy in younger and elderly patients with advanced biliary cancer: Sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer, 17(1), 1-9. [More Information]

2015

  • Stein, A., Arnold, D., Bridgewater, J., Goldstein, D., Jensen, L., Klumpen, H., Lohse, A., Nashan, B., Primrose, J., Schrum, S., Shannon, J., et al (2015). Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 15(1), 1-8. [More Information]

2014

  • Greenhalf, W., Ghaneh, P., Neoptolemos, J., Palmer, D., Cox, T., Lamb, R., Garner, E., Campbell, F., Mackey, J., Costello, E., Shannon, J., et al (2014). Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. Journal of the National Cancer Institute, 106(1), 1-10. [More Information]
  • Ringash, J., Au, H., Siu, L., Shapiro, J., Jonker, D., Zalcberg, J., Moore, M., Strickland, A., Kotb, R., Jeffery, M., Shannon, J., El-Tahche, F., et al (2014). Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer, 120(2), 181-189. [More Information]

2011

  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Parry, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]

2009

  • Oddone, N., Morgan, G., Palme, C., Perera, L., Shannon, J., Wong, E., Gebski, V., Veness, M. (2009). Metastatic cutaneous squamous cell carcinoma of the head and neck: the Immunosuppression, Treatment, Extranodal spread, and Margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer, 115(9), 1883-1891. [More Information]

2008

  • Dear, R., Wilcken, N., Shannon, J. (2008). Beyond chemotherapy: Demystifying the new 'targeted' cancer treatments. Australian Family Physician, 37(1-2), 45-49. [More Information]

2006

To update your profile click here. For support on your academic profile contact .